Clinical Trial Update: The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating a topical palmitoylethanolamide (Levagen+) formulation for reducing symptoms of atopic dermatitis (eczema) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Levagen+

Snippet

Sponsor: RDC Clinical Pty Ltd | Conditions: Eczema, Atopic | Phase 2, Phase 3 | Status: COMPLETED